Taikang Asset Management (Hong Kong) CO LTD Crinetics Pharmaceuticals, Inc. Transaction History
Taikang Asset Management (Hong Kong) CO LTD
- $667 Million
- Q4 2024
A detailed history of Taikang Asset Management (Hong Kong) CO LTD transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Taikang Asset Management (Hong Kong) CO LTD holds 8,500 shares of CRNX stock, worth $305,490. This represents 0.07% of its overall portfolio holdings.
Number of Shares
8,500
Previous 8,500
-0.0%
Holding current value
$305,490
Previous $434,000
-0.0%
% of portfolio
0.07%
Previous 0.05%
Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
254Shares Held
82.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$327 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$224 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$221 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$195 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.29MShares$154 Million10.24% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.93B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...